Upjohn Co. said it acquired U.S. and Canadian marketing rights for the cancer compound irinotecan from Yakult Honsha of Tokyo.
In return, Upjohn said it granted Yakult Honsha co-development and co-marketing rights in Japan for Upjohn's cancer drug adozelesin.
Daiichi Pharmaceuticals Co. Ltd. of Tokyo will continue to collaborate on the development of irinotecan and co-promote the drug with Upjohn in the U.S.
